NCT01097408已完成1 期
A Randomised, Double-Blind, Placebo-Controlled Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD7295 Capsules in Healthy Volunteers
Arrow Therapeutics1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2010年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Pharmacokinetics of AZD7295 capsules
研究概览
简要总结
This is a pharmacokinetics (PK) and safety study of AZD7295 in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female volunteers, aged 18-65 years.
排除标准
- •Previous exposure to AZD7295, clinically relevant disease.
研究组 & 干预措施
AZD7295
Experimental
干预措施: AZD7295 (Drug)
Matched placebo
Placebo Comparator
干预措施: Placebo comparator (Drug)
结局指标
主要结局
Pharmacokinetics of AZD7295 capsules
时间窗: 0-72h after each dose
PK parameters of AZD7295 will be measured after single and repeated doses (AUC, Cmax, t1/2)
次要结局
- Safety and tolerability of AZD7295 capsules(0-72h after each dose)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551HealthyNCT00860353AstraZeneca90
已完成
1 期
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.Heathy ParticipantsNCT06093542AstraZeneca12
已完成
1 期
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy ParticipantsHealthy ParticipantsNCT06502379AstraZeneca147
已完成
1 期
Single and Multiple Ascending Doses of AZD1981 in JapanHealthyNCT00698282AstraZeneca47
已完成
1 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy ParticipantsHealthy Participants StudyNCT06311760AstraZeneca17